ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Syngene, India’s largest contract research organization (CRO), has raised $85 million from an initial public offering (IPO) on India’s National Stock Exchange. Demand was strong for the stock, which went up 23% on its first day of trading. Based in Bangalore, Syngene is a subsidiary of Biocon, India’s largest biotechnology company. Outside India, public listings by CROs have had mixed success. China’s WuXi Apptec and ShangPharma also had successful IPOs. But ShangPharma opted to delist itself from the New York Stock Exchange in 2013, about two-and-a-half years after its IPO. WuXi, listed in New York since 2007, is currently considering an offer by its founder to go private again.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X